Skip to main content
. 2023 Jun 1;216:105651. doi: 10.1016/j.antiviral.2023.105651

Fig. 2.

Fig. 2

Inhibition of VACV and CPXV replication by trifluridine and Adefovir dipivoxil (ADP) by plaque assay. (A) Structures of trifluridine (TFD, 4), adefovir dipivoxil (ADP, 5), and AraC (6). (B) HFFs were infected with VACV at an MOI of 0.01 and treated with indicated compounds at 10 μM for 48 h. Viral yields were titrated using a plaque assay using BS-C-1 cells. (C) HFF cell viability was measured 48 h after the cells were treated with indicated compounds at 10 μM. (D) HFFs were infected with CPXV at an MOI of 0.01 and treated with indicated compounds at 10 μM for 48 h. Viral yields were titrated using a plaque assay using BS-C-1 cells. The plotted values represent the means of at least three repeats. Error bars represent standard deviation. **0.001<p ≤ 0.01; ****0.00001<p ≤ 0.0001; ns, not significant.